

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	CORRECTIVE ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Corrective Assignment to correct the listing of trademarks on Sched. II of the Security Agreement to remove U.S. TM Reg. Nos. 2059777, 571968, 652637 and 2781023 previously recorded on Reel 004305 Frame 0290. Assignor(s) hereby confirms the security interest in the TMs, other than Reg. Nos. 2059777, 571968, 652637 & 2781023, in which it never had a security interest.

**CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
COREPHARMA, L.L.C.		10/22/2010	LIMITED LIABILITY COMPANY: DELAWARE
COREPHARMA, INC.		10/22/2010	CORPORATION: DELAWARE
COREPHARMA HOLDINGS, INC.		10/22/2010	CORPORATION: DELAWARE
AMEDRA PHARMACEUTICALS, LLC		10/22/2010	LIMITED LIABILITY COMPANY: DELAWARE

**RECEIVING PARTY DATA**

<b>Name:</b>	GENERAL ELECTRIC CAPITAL CORPORATION
<b>Street Address:</b>	500 WEST MONROE STREET
<b>City:</b>	CHICAGO
<b>State/Country:</b>	ILLINOIS
<b>Postal Code:</b>	60661
<b>Entity Type:</b>	CORPORATION: DELAWARE

**PROPERTY NUMBERS Total: 9**

Property Type	Number	Word Mark
Registration Number:	1177791	DEXEDRINE
Registration Number:	2351465	COREPHARMA, LLC
Registration Number:	2059777	ALBENZA
Registration Number:	0571968	DARAPRIM
Registration Number:	0652637	SPANSULE
Registration Number:	2781023	
Serial Number:	77936227	COREPHARMA
Serial Number:	77936220	COREPHARMA

Serial Number:

77932673

AMEDRA

**CORRESPONDENCE DATA**

**Fax Number:** (404)541-3255

*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*

**Phone:** 404-815-6500

**Email:** mcogburn@kilpatrickstockton.com

**Correspondent Name:** Laura Phillips, Kilpatrick Stockton LLP

**Address Line 1:** 1100 Peachtree Street

**Address Line 2:** Suite 2800

**Address Line 4:** Atlanta, GEORGIA 30309

**ATTORNEY DOCKET NUMBER:**

317662

**NAME OF SUBMITTER:**

Margaret A. Cogburn

**Signature:**

/Margaret A. Cogburn/

**Date:**

11/17/2010

**Total Attachments: 20**

source=Notice of Recordation#page1.tif

source=Notice of Recordation#page2.tif

source=Notice of Recordation#page3.tif

source=Notice of Recordation#page4.tif

source=Notice of Recordation#page5.tif

source=Notice of Recordation#page6.tif

source=GE\_CorePharma- A&R Intellectual Property Security Agreement#page1.tif

source=GE\_CorePharma- A&R Intellectual Property Security Agreement#page2.tif

source=GE\_CorePharma- A&R Intellectual Property Security Agreement#page3.tif

source=GE\_CorePharma- A&R Intellectual Property Security Agreement#page4.tif

source=GE\_CorePharma- A&R Intellectual Property Security Agreement#page5.tif

source=GE\_CorePharma- A&R Intellectual Property Security Agreement#page6.tif

source=GE\_CorePharma- A&R Intellectual Property Security Agreement#page7.tif

source=GE\_CorePharma- A&R Intellectual Property Security Agreement#page8.tif

source=GE\_CorePharma- A&R Intellectual Property Security Agreement#page9.tif

source=GE\_CorePharma- A&R Intellectual Property Security Agreement#page10.tif

source=GE\_CorePharma- A&R Intellectual Property Security Agreement#page11.tif

source=GE\_CorePharma- A&R Intellectual Property Security Agreement#page12.tif

source=GE\_CorePharma- A&R Intellectual Property Security Agreement#page13.tif

source=GE\_CorePharma- A&R Intellectual Property Security Agreement#page14.tif

TO: LAURA PHILLIPS, ESQ. COMPANY: KILPATRICK STOCKTON LLP



## UNITED STATES PATENT AND TRADEMARK OFFICE

### Facsimile Transmission

**To:**                   **Name:**                   LAURA PHILLIPS, ESQ.  
                          **Company:**               KILPATRICK STOCKTON LLP  
                          **Fax Number:**           14045414710  
                          **Voice Phone:**

**From:**               **Name:**                   ASSIGNMENT SERVICES BRANCH  
                          **Voice Phone:**         571-272-3350

37 C.F.R. 1.6 sets forth the types of correspondence that can be communicated to the Patent and Trademark Office via facsimile transmissions. Applicants are advised to use the certificate of facsimile transmission procedures when submitting a reply to a non-final or final Office action by facsimile (37 CFR 1.8(a)).

#### Fax Notes:

---

Pg#	Description
1	Cover Page
2	172.TXT
5	Document 1, Batch 2225602

USPTO ASSIGNMENT SYSTEM PROCESSING

---

Date and time of transmission: Thursday, October 28, 2010 11:34:52 AM  
Number of pages including this cover sheet: 06

---

**TRADEMARK**  
**REEL: 004416 FRAME: 0518**

TO: LAURA PHILLIPS, ESQ. COMPANY: KILPATRICK STOCKTON LLP

**UNITED STATES PATENT AND TRADEMARK OFFICE**UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND  
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

OCTOBER 28, 2010

\*900175089A\*

PTAS

LAURA PHILLIPS, ESQ.  
KILPATRICK STOCKTON LLP  
1100 PEACHTREE STREET, SUITE 2800  
ATLANTA, GA 30309UNITED STATES PATENT AND TRADEMARK OFFICE  
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENTTHE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF  
THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS  
AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER  
REFERENCED BELOW.PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE  
INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA  
PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD  
FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY  
CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 571-272-3350.  
PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE,  
MAIL STOP: ASSIGNMENT SERVICES BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 10/27/2010

REEL/FRAME: 004305/0290  
NUMBER OF PAGES: 16BRIEF: SECURITY INTEREST  
DOCKET NUMBER: 317662

## ASSIGNOR:

COREPHARMA, L.L.C.

DOC DATE: 10/22/2010  
CITIZENSHIP: NEW JERSEY  
ENTITY: LIMITED LIABILITY  
COMPANY

## ASSIGNOR:

COREPHARMA, INC.

DOC DATE: 10/22/2010  
CITIZENSHIP: DELAWARE  
ENTITY: CORPORATION

## ASSIGNOR:

COREPHARMA HOLDINGS, INC.

DOC DATE: 10/22/2010  
CITIZENSHIP: DELAWARE  
ENTITY: CORPORATION

TO: LAURA PHILLIPS, ESQ. COMPANY: KILPATRICK STOCKTON LLP

004305/0290 PAGE 2

## ASSIGNOR:

AMEDRA PHARMACEUTICALS LLC

DOC DATE: 10/22/2010  
CITIZENSHIP: DELAWARE  
ENTITY: LIMITED LIABILITY  
COMPANY

## ASSIGNEE:

GENERAL ELECTRIC CAPITAL  
CORPORATION  
500 WEST MONROE STREET  
CHICAGO, ILLINOIS 60661CITIZENSHIP: DELAWARE  
ENTITY: CORPORATIONAPPLICATION NUMBER: 77936227  
REGISTRATION NUMBER:FILING DATE: 02/16/2010  
ISSUE DATE:

## MARK: COREPHARMA

DRAWING TYPE: WORDS, LETTERS, OR NUMBERS IN BLOCK FORM

APPLICATION NUMBER: 77936220  
REGISTRATION NUMBER: 3849981FILING DATE: 02/16/2010  
ISSUE DATE: 09/21/2010

## MARK: COREPHARMA

DRAWING TYPE: WORDS, LETTERS, OR NUMBERS IN BLOCK FORM

APPLICATION NUMBER: 77932673  
REGISTRATION NUMBER:FILING DATE: 02/10/2010  
ISSUE DATE:

## MARK: AMEDRA

DRAWING TYPE: WORDS, LETTERS, OR NUMBERS IN BLOCK FORM

APPLICATION NUMBER: 74638089  
REGISTRATION NUMBER: 2059777FILING DATE: 02/22/1995  
ISSUE DATE: 05/06/1997

## MARK: ALBENZA

DRAWING TYPE: WORDS, LETTERS, OR NUMBERS IN TYPED FORM

APPLICATION NUMBER: 71618386  
REGISTRATION NUMBER: 571968FILING DATE: 09/05/1951  
ISSUE DATE: 03/17/1953

## MARK: DARAPRIM

DRAWING TYPE: WORDS, LETTERS, OR NUMBERS IN TYPED FORM

APPLICATION NUMBER: 73266838  
REGISTRATION NUMBER: 1177791FILING DATE: 06/18/1980  
ISSUE DATE: 11/17/1981

## MARK: DEXEDRINE

DRAWING TYPE: WORDS, LETTERS, OR NUMBERS IN TYPED FORM

APPLICATION NUMBER: 72016757  
REGISTRATION NUMBER: 652637FILING DATE: 10/01/1956  
ISSUE DATE: 10/08/1957

## MARK: SPANSULE

DRAWING TYPE: WORDS, LETTERS, OR NUMBERS IN TYPED FORM

TO: LAURA PHILLIPS, ESQ. COMPANY: KILPATRICK STOCKTON LLP

004305/0290 PAGE 3

APPLICATION NUMBER: 76024337  
REGISTRATION NUMBER: 2781023

FILING DATE: 04/12/2000  
ISSUE DATE: 11/11/2003

MARK:

DRAWING TYPE: MISCELLANEOUS DESIGN

APPLICATION NUMBER: 75598302  
REGISTRATION NUMBER: 2351465

FILING DATE: 12/02/1998  
ISSUE DATE: 05/23/2000

MARK: COREPHARMA, LLC

DRAWING TYPE: STYLIZED WORDS, LETTERS, OR NUMBERS

ALLYSON PURNELL, EXAMINER  
ASSIGNMENT SERVICES BRANCH  
PUBLIC RECORDS DIVISION

**TRADEMARK**  
**REEL: 004416 FRAME: 0521**

<b>TRADEMARK ASSIGNMENT</b>
-----------------------------

Electronic Version v1.1  
 Stylesheet Version v1.1

**10/27/2010**  
**900175089**

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST

**CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
CorePharma, L.L.C.		10/22/2010	LIMITED LIABILITY COMPANY: NEW JERSEY
CorePharma, Inc.		10/22/2010	CORPORATION: DELAWARE
CorePharma Holdings, Inc.		10/22/2010	CORPORATION: DELAWARE
Amedra Pharmaceuticals LLC		10/22/2010	LIMITED LIABILITY COMPANY: DELAWARE

**RECEIVING PARTY DATA**

<b>Name:</b>	General Electric Capital Corporation
<b>Street Address:</b>	500 West Monroe Street
<b>City:</b>	Chicago
<b>State/Country:</b>	ILLINOIS
<b>Postal Code:</b>	60661
<b>Entity Type:</b>	CORPORATION: DELAWARE

**PROPERTY NUMBERS Total: 9**

Property Type	Number	Word Mark
Registration Number:	2059777	ALBENZA
Registration Number:	0571968	DARAPRIM
Registration Number:	1177791	DEXEDRINE
Registration Number:	0652637	SPANSULE
Registration Number:	2781023	
Serial Number:	77936227	COREPHARMA
Serial Number:	77936220	COREPHARMA
Registration Number:	2351465	COREPHARMA, LLC
Serial Number:	77932673	AMEDRA

**CORRESPONDENCE DATA**

**TRADEMARK**  
**REEL: 004416 FRAME: 0522**

OP \$240.00 2059777

TO: LAURA PHILLIPS, ESQ. COMPANY: KILPATRICK STOCKTON LLP

**Fax Number:** (404)541-4710  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
**Phone:** 404-815-6034  
**Email:** laallen@kilpatrickstockton.com  
**Correspondent Name:** Laura Phillips, Esq.  
**Address Line 1:** Kilpatrick Stockton LLP  
**Address Line 2:** 1100 Peachtree Street, Suite 2800  
**Address Line 4:** Atlanta, GEORGIA 30309

<b>ATTORNEY DOCKET NUMBER:</b>	317662
<b>NAME OF SUBMITTER:</b>	Latosha E. Allen
<b>Signature:</b>	/Latosha E. Allen/
<b>Date:</b>	10/27/2010

**Total Attachments: 14**

source=A&R Intellectual Property Security Agreement #page1.tif  
source=A&R Intellectual Property Security Agreement #page2.tif  
source=A&R Intellectual Property Security Agreement #page3.tif  
source=A&R Intellectual Property Security Agreement #page4.tif  
source=A&R Intellectual Property Security Agreement #page5.tif  
source=A&R Intellectual Property Security Agreement #page6.tif  
source=A&R Intellectual Property Security Agreement #page7.tif  
source=A&R Intellectual Property Security Agreement #page8.tif  
source=A&R Intellectual Property Security Agreement #page9.tif  
source=A&R Intellectual Property Security Agreement #page10.tif  
source=A&R Intellectual Property Security Agreement #page11.tif  
source=A&R Intellectual Property Security Agreement #page12.tif  
source=A&R Intellectual Property Security Agreement #page13.tif  
source=A&R Intellectual Property Security Agreement #page14.tif



AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY  
AGREEMENT

**THIS AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT** (this "Intellectual Property Security Agreement"), dated as of October 22, 2010, is made by the Persons named on Schedule V hereto and signatory hereto (each a "Grantor" and, collectively, the "Grantors"), with offices at the locations set forth on Schedule IV hereto, in favor of **GENERAL ELECTRIC CAPITAL CORPORATION**, a Delaware corporation, acting in its capacity as Administrative Agent for the Lending Parties under the Amended and Restated Credit Agreement described below, with offices at 500 West Monroe Street, Chicago, Illinois 60661 (the "Administrative Agent").

**WITNESSETH:**

**WHEREAS**, pursuant to that certain Amended and Restated Credit Agreement dated as of the date hereof by and among CorePharma, LLC (the "Borrower"), the other Credit Parties signatory thereto, the Lending Parties signatory thereto and General Electric Capital Corporation (collectively, the "Lending Parties") (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented, extended replaced or otherwise modified, the "Credit Agreement"), the Lending Parties have agreed to make certain financial accommodations (including but not limited to the Loans) for the benefit of the Borrower and the other Grantors;

**WHEREAS**, pursuant to that certain Intellectual Property Security Agreement dated as of August 4, 2005 (as amended, restated, supplemented or otherwise modified from time to time, the "Existing IP Security Agreement"), by and among Borrower and Existing Agent, Borrower has granted to the Existing Agent for the benefit of itself and the Existing Lenders a Lien upon all of its right, title and interest in, to and under the in the 'Intellectual Property Collateral' (as defined therein);

**WHEREAS**, each of the parties to the Credit Agreement have agreed to amend and restate in its entirety the Existing IP Security Agreement pursuant to this Intellectual Property Security Agreement, it being their intention that this Intellectual Property Security Agreement shall not be construed as constituting a release of any prior grant of any security interest under the Existing IP Security Agreement by any Grantor in favor of Administrative Agent, as Existing Lender or Existing Agent, or as Administrative Agent or Lending Party, but is intended to constitute a restatement and reconfirmation of the prior grant in favor of Administrative Agent (for the benefit of itself and the other Lending Parties);

**WHEREAS**, Administrative Agent and the Lending Parties are willing to make the financial accommodations as provided for in the Credit Agreement, but only upon the condition, among others, that Borrower and each Guarantor (including the Grantors) shall have executed and delivered to the Administrative Agent, for itself and the ratable benefit of Lending Parties, that certain Borrower Security Agreement, that certain Holdings Security Agreement, that certain Parent Security Agreement or that certain Subsidiary Security Agreement, as applicable, each dated as of the date hereof (including all annexes, exhibits or schedules thereto, as from time to

time amended, restated, supplemented or otherwise modified, collectively, the "Security Agreements");

**WHEREAS**, pursuant to the Credit Agreement and the Security Agreements, each Grantor is required to execute and deliver to Administrative Agent, for itself and the ratable benefit of the Lending Parties, this Intellectual Property Security Agreement.

**NOW, THEREFORE**, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor hereby agrees as follows:

1. **Definitions.** All capitalized terms used but not otherwise defined herein have the meanings given to them in **Section 1.1** of the Credit Agreement.

2. **Grant of Security Interest.** To secure the prompt and complete payment and performance of all of the Obligations, each Grantor hereby grants, assigns, conveys, mortgages, pledges, hypothecates and transfers to Administrative Agent, for itself and the benefit of the Lending Parties, a Lien upon all of its right, title and interest of such Grantor in, to and under the following, whether presently existing or hereafter created or acquired (collectively, with respect to each Grantor, the "Intellectual Property Collateral"):

(a) all of its Patents including those referred to on Schedule I hereto and Patent Licenses to which it is a party;

(b) all of its Trademarks including those referred to on Schedule II hereto and Trademark Licenses to which it is a party;

(c) all of its Copyrights including those referred to on Schedule III hereto and Copyright Licenses to which it is a party;

(d) all reissues, continuations or extensions of the foregoing;

(e) all goodwill of the business connected with the use of, and symbolized by, each Patent, each Patent License, each Trademark, each Trademark License, each Copyright and each Copyright License; and

(f) all products and proceeds of the foregoing, including, without limitation, any claim by such Grantor against third parties for past, present or future (i) infringement or dilution of any Patent or Patent licensed under any Patent License, (ii) injury to the goodwill associated with any Patent or any Patent licensed under any Patent License, (iii) infringement or dilution of any Trademark or Trademark licensed under any Trademark License, (iv) injury to the goodwill associated with any Trademark or any Trademark licensed under any Trademark License, (v) infringement or dilution of any Copyright or Copyright licensed under any Copyright License, and (vi) injury to the goodwill associated with any Copyright or any Copyright licensed under any Copyright License.

Notwithstanding anything in this Section to the contrary, the following shall not constitute "Intellectual Property Collateral" hereunder: any intent-to-use trademark application

to the extent and for so long as creation by the Grantor of a security interest therein would result in the abandonment, invalidation or unenforceability thereof.

3. **Representations and Warranties.** Each Grantor represents and warrants to the Administrative Agent and the Lending Parties that such Grantor does not have any interest in, or title to, any Patent, registered Trademark or registered Copyright except as set forth in Schedule I, Schedule II and Schedule III, respectively, hereto. This Intellectual Property Security Agreement is effective to create a valid and continuing Lien on and, upon the recording hereof by the United States Copyright Office and the United States Patent and Trademark Office, perfected Liens in favor of Administrative Agent (for the benefit of itself and the Lending Parties) on each Grantor's Patents, Trademarks and Copyrights and such perfected Liens are enforceable as such as against any and all creditors of and purchasers from any Grantor to the extent that recording in the United States Copyright Office and the United States Patent and Trademark Office is effective to do so and subject to the proviso in the next sentence. Upon recording of this Intellectual Property Security Agreement by the United States Copyright Office and the United States Patent and Trademark Office and the filing of appropriate financing statements in the jurisdictions listed on Schedule I to the Security Agreements, all action necessary or desirable to protect and perfect Administrative Agent's Lien on each Grantor's Patents, Trademarks or Copyrights shall have been duly taken; provided, however, that the subsequent recordation of this Intellectual Property Security Agreement in the U.S. Patent and Trademark Office and U.S. Copyright Office, as applicable, may be necessary to perfect the security interest of the Administrative Agent in issued registrations and applications for other U.S. Intellectual Property that are acquired by any Grantor after the date hereof, the registration of unregistered Copyrights in the U.S. Copyright Office may be required in order to perfect the Administrative Agent's Lien therein, and the taking of actions outside the United States may be required in order to perfect the Administrative Agent's Lien in Intellectual Property included in the Collateral which is protected under non-U.S. law.

4. **Covenants.** Each Grantor covenants and agrees with the Administrative Agent that from and after the date of this Intellectual Property Security Agreement and until the Commitment Termination Date:

(a) Grantors shall notify Administrative Agent immediately if they know or have reason to know that any material application or registration relating to any Patent, Trademark or Copyright (now or hereafter existing) may become abandoned or dedicated to the public, or of any adverse determination or development (including the institution of, or any such determination or development in, any proceeding in the United States Patent and Trademark Office, the United States Copyright Office or any court) regarding any Grantor's ownership of any Patent, Trademark or Copyright, its right to register the same, or to keep and maintain the same.

(b) Grantors shall provide Administrative Agent with written notice of any application filed by any Grantor, either by itself or through any agent, employee, licensee or designee, to register any Patent, Trademark or Copyright with the United States Patent and Trademark Office, the United States Copyright Office or any similar office or agency in the United States within ninety (90) days of such filing, and, upon request of Administrative Agent, such Grantor shall execute and deliver a supplement hereto as

Administrative Agent may request to evidence Administrative Agent's Lien on such Patent, Trademark or Copyright, and the General Intangibles of such Grantor relating thereto or represented thereby.

(c) Grantors shall take all commercially reasonable actions necessary or requested by Administrative Agent to maintain and pursue each application, to obtain the relevant registration and to maintain the registration of each of the Patents, Trademarks and Copyrights (now or hereafter existing), including the filing of applications for renewal, affidavits of use, affidavits of noncontestability and opposition and interference and cancellation proceedings, except where the failure to do so could not reasonably be expected to have a Material Adverse Effect.

(d) In the event that any of the Intellectual Property Collateral is infringed upon, or misappropriated or diluted by a third party, such Grantor shall (1) comply with Section 5(a)(ix) of the Security Agreements and (2) unless such Grantor shall reasonably determine that such Intellectual Property Collateral is not material to the conduct of its business or operations, promptly take all commercially reasonable actions, including to sue to enjoin any such conduct and/or to recover any and all damages for such infringement, misappropriation or dilution.

5. **Security Agreement.** The security interests granted by each Grantor pursuant to this Intellectual Property Security Agreement are granted in conjunction with the security interest granted by each Grantor to Administrative Agent, on behalf of itself and the Lending Parties, pursuant to the Security Agreements. Each Grantor and Administrative Agent expressly agree that the security interests granted under this Intellectual Property Security Agreement and the Security Agreements in the Intellectual Property Collateral are intended to be treated as a single security interest for purposes of Article 9 of the Code and other applicable law. The exercise by the Administrative Agent or the Lending Parties of any rights or remedies with respect to any of the Intellectual Property Collateral shall be deemed to be an exercise of such rights or remedies in connection with both this Intellectual Property Security Agreement and the Security Agreements. In the event of any inconsistency between the terms and conditions of this Intellectual Property Security Agreement and the Security Agreements, then the terms and conditions of the Security Agreements shall prevail.

6. **Reinstatement.** This Intellectual Property Security Agreement shall remain in full force and effect and continue to be effective should any petition be filed by or against any Grantor for liquidation or reorganization, should any Grantor become insolvent or make an assignment for the benefit of any creditor or creditors or should a receiver or trustee be appointed for all or any significant part of any Grantor's assets, and shall continue to be effective or be reinstated, as the case may be, if at any time payment and performance of the Obligations, or any part thereof, is, pursuant to applicable law, rescinded or reduced in amount, or must otherwise be restored or returned by any obligee of the Obligations, whether as a "voidable preference," "fraudulent conveyance," or otherwise, all as though such payment or performance had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, restored or returned, the Obligations shall be reinstated and deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned.

7. **Notices.** Whenever it is provided herein that any notice, demand, request, consent, approval, declaration or other communication shall or may be given to or served upon any of the parties by any other party, or whenever any of the parties desires to give and serve upon any other party any communication with respect to this Intellectual Property Security Agreement, each such notice, demand, request, consent, approval, declaration or other communication shall be in writing and shall be given in the manner, and deemed received, as provided for in the Credit Agreement.

8. **Termination; Authorized Sales of Collateral.** Subject to Section 6 hereof, this Intellectual Property Security Agreement shall terminate upon the Commitment Termination Date. In the event any Grantor proposes to sell any of the Intellectual Property Collateral and such sale is permitted pursuant to the terms and conditions set forth in Section 7.8 of the Credit Agreement, the Administrative Agent agrees, at the expense of such Grantor, to execute and deliver to such Grantor, prior to or contemporaneously with Grantor's receipt of the proceeds from such sale, such UCC-3 termination statements and other collateral property releases necessary to release the applicable Intellectual Property Collateral from the lien and security interest of the Administrative Agent.

9. **Amendment and Restatement.** This Intellectual Property Security Agreement constitutes an amendment and restatement of the Existing IP Security Agreement effective from and after the date hereof. The execution and delivery of this Intellectual Property Security Agreement and the consummation of the transactions contemplated hereby are not intended by the parties to be, and shall not constitute, a novation or an accord and satisfaction of the Obligations or any other obligations owing to General Electric Capital Corporation, in its capacities as Existing Agent and an Existing Lender under the Existing Credit Agreement or any other Existing Loan Document. Each of the parties hereto hereby acknowledges and agrees that the grant of Liens pursuant to this Intellectual Property Security Agreement is not intended to, nor shall it be construed, as constituting a release of any prior grant by any Grantor in favor of General Electric Capital Corporation, in its capacities as Existing Agent and an Existing Lender under the Existing Credit Agreement or any other Existing Loan Document, or as Administrative Agent or Lending Party, but is intended to constitute a restatement and reconfirmation of the prior grant in favor of Administrative Agent (for the benefit of itself and the other Lending Parties).

10. **Governing Law.** THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF ILLINOIS. GRANTORS HEREBY SUBMIT TO THE NONEXCLUSIVE JURISDICTION OF THE FEDERAL AND/OR STATE COURTS SITTING IN COOK COUNTY, CITY OF CHICAGO, ILLINOIS FOR PURPOSES OF ALL LEGAL PROCEEDINGS ARISING OUT OF OR RELATING TO THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. GRANTORS IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH ANY OF THEM MAY NOW OR HEREAFTER HAVE TO THE LAYING OF THE VENUE OF ANY SUCH PROCEEDING BROUGHT IN SUCH A COURT AND ANY CLAIM THAT ANY SUCH PROCEEDING BROUGHT IN SUCH A COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. EACH OF THE PARTIES HERETO IRREVOCABLY CONSENTS TO SERVICE OF


PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 11.3 OF THE CREDIT AGREEMENT. NOTHING IN THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY TO THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]


IN WITNESS WHEREOF, each Grantor has caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer or other representative as of the date first set forth above.

**GRANTORS:**


**COREPHARMA, L.L.C.**

By:   
Name: Ernest R. De Paolantonio  
Title: Authorized Person


**COREPHARMA, INC.**

By:   
Name: Ernest R. De Paolantonio  
Title: Authorized Person

**COREPHARMA HOLDINGS, INC.**

By:   
Name: Ernest R. De Paolantonio  
Title: Authorized Person

**AMEDRA PHARMACEUTICALS LLC**

By:   
Name: Ernest R. De Paolantonio  
Title: Authorized Person

**ACCEPTED AND ACKNOWLEDGED BY:**

**GENERAL ELECTRIC CAPITAL CORPORATION,**  
as Administrative Agent

By: \_\_\_\_\_  
Name: Brent Shepherd  
Title: Duly Authorized Signatory

INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**IN WITNESS WHEREOF**, each Grantor has caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer or other representative as of the date first set forth above.

**GRANTORS:**

**COREPHARMA, L.L.C.**

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

**COREPHARMA, INC.**

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

**COREPHARMA HOLDINGS, INC.**


By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

**AMEDRA PHARMACEUTICALS, LLC**

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

**ACCEPTED AND ACKNOWLEDGED BY:**

**GENERAL ELECTRIC CAPITAL CORPORATION,**  
as Administrative Agent

By:  \_\_\_\_\_  
Name: Brent Shepherd  
Title: Duly Authorized Signatory

INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004416 FRAME: 0531**



ACKNOWLEDGMENT OF GRANTORS

STATE OF NJ  
COUNTY OF Monmouth

On this 21 day of October, 2010, before me personally appeared Ernest R. De Paolantonio, proved to me on the basis of satisfactory evidence to be the person who executed the foregoing instrument on behalf of the following entities:

- CorePharma, L.L.C.
- CorePharma, Inc.
- CorePharma Holdings, Inc.
- Amedra Pharmaceuticals LLC

who being by me duly sworn did depose and say that he is the Authorized Person of said company, that the said instrument was signed on behalf of said company as authorized by its Board of Directors (or equivalent governing body) and that he acknowledged said instrument to be the free act and deed of said company.

Tara Sutton  
Notary Public

{seal}

Tara Sutton  
Notary Public  
New Jersey

SCHEDULE I  
to  
INTELLECTUAL PROPERTY SECURITY AGREEMENT

I. PATENT REGISTRATIONS

None.

II. PATENT APPLICATIONS

None.

III. PATENT LICENSES

None.

**SCHEDULE II**  
to  
**INTELLECTUAL PROPERTY SECURITY AGREEMENT**

**I. TRADEMARK REGISTRATIONS**

US Trademark Reg. No. 1,177,791 for the DEXEDRINE word mark  
US Trademark Reg. No. 77,936,227 for CorePharma word mark  
US Trademark Reg. No. 77,936,220 for CorePharma word mark  
US Trademark Reg. No. 2,351,465 for CorePharma, LLC word mark  
US Trademark Reg. No. 77,932,673 for Amedra word mark

**II. TRADEMARK APPLICATIONS**

None.

**III. TRADEMARK LICENSES**

None.

SCHEDULE III  
to  
INTELLECTUAL PROPERTY SECURITY AGREEMENT

I. COPYRIGHT REGISTRATIONS

None.

II. COPYRIGHT APPLICATIONS

None.

III. COPYRIGHT LICENSES

None.

SCHEDULE IV  
to  
INTELLECTUAL PROPERTY SECURITY AGREEMENT

1. Names of each Grantor:

CorePharma, L.L.C.

CorePharma, Inc.

CorePharma Holdings, Inc.

Amedra Pharmaceuticals LLC

2. Office location of each Grantor:

CorePharma, L.L.C.:

215 Wood Ave., Middlesex, New Jersey 08846

CorePharma, Inc.:

215 Wood Ave., Middlesex, New Jersey 08846

CorePharma Holdings, Inc.:

215 Wood Ave., Middlesex, New Jersey 08846

Amedra Pharmaceuticals LLC:

215 Wood Ave., Middlesex, New Jersey 08846

**SCHEDULE V**  
**to**  
**INTELLECTUAL PROPERTY SECURITY AGREEMENT**

**CorePharma, L.L.C.**

**CorePharma, Inc.**

**CorePharma Holdings, Inc.**

**Amedra Pharmaceuticals LLC**

US2000 11918933.2

**RECORDED: 11/17/2010**

**TRADEMARK**  
**REEL: 004416 FRAME: 0537**